8 research outputs found
Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis
No full textMMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure
No full textAngiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor β1 in the Rat Heart
No full textHeterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function
No full text
Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study
No full textNuevos farmacos en insuficiencia cardíaca
No full textLa insuficiencia cardíaca es un problema de salud pública importante que ha tenido un incremento significativo en incidencia y prevalencia en las dos últimas décadas.
A pesar de la mejora de la terapia médica actual, la insuficiencia cardíaca está asociada a una morbilidad y mortalidad significativas. Esto ha motivado la búsqueda de nuevas opciones terapéuticas, basadas en un mejor entendimiento de los procesos fisiopatológicos que conducen a insuficiencia cardíaca.
En esta revisión se resume el papel potencial de los nuevos agentes farmacológicos en el tratamiento de la insuficiencia cardíaca. Estos nuevos agentes pueden clasificarse de acuerdo con su papel en la modulación de las más importantes anormalidades fisiopatológicas que caracterizan la insuficiencia cardíaca, que incluyen: anormalidades celulares y de la matriz extracelular, disfunción endotelial y activación neurohormonal e inmunológica.
Heart failure is a common and growing public health problem, with increasing incidence and prevalence over the last 2 decades.
Despite improvements in its current management, heart failure is still associated with significant morbidity and mortality. This has motivated the search for newer therapeutic modalities, which are based on a better understanding on the pathophysiologic events that lead to heart failure.
This review summarizes the potential role of new pharmacological agents in the treatment of heart failure. These potential new agents can be classified according to their role in the modulation of the main pathophysiologic abnormalities that characterized heart failure, that include: cellular-extracellular abnormalities, endothelial dysfunction, neurohormonal and immunologic activation
